ArticleInternational journal of endocrinology2026
Trends in Clinical Features of Primary Hyperparathyroidism During 2013-2024.
Article in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Parathyroid Carcinoma Revisited: Clinical and Pathological Insights From Two Decades of Experience.Clinical endocrinology · 2026Article
- Future Directions in Hypercalcemic and Normocalcemic Primary Hyperparathyroidism: FRAXplus for 10-Year Fracture Risk Assessment (A Retrospective Study).Life (Basel, Switzerland) · 2026Article
- Trends in Clinical Features of Primary Hyperparathyroidism During 2013-2024.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Clinical features of primary hyperparathyroidism (PHPT) differ between developed and developing countries. In past decades, patterns of PHPT have changed while there are currently few data on large cohorts in Chinese. Therefore, this study aims to describe changes in clinical features of Chinese patients with PHPT. Materials and Methods: 685 patients with PHPT were collected and divided into several subgroups by time periods, symptoms, and pathological types. Clinical characteristics were compared among subgroups. Results: Patients were divided into 177 cases (25.8%) in group A (2013-2018) and 508 cases (74.2%) in group B (2019-2024). Compared with group A, parathyroid hormone (PTH) was significantly lower and clinical manifestations were milder, and the percentage of asymptomatic patients was higher in group B. Bone pain (46.8%), nephrolithiasis (37.3%), and fatigue (36.2%) were the most common symptoms in symptomatic patients. Serum PTH, calcium, osteocalcin, and urine pH levels in symptomatic patients were higher than those in asymptomatic patients, while serum phosphate and bone density levels were lower. In addition, among 417 surgical patients, benign parathyroid tumor was in 373 cases (89.4%), atypical parathyroid tumor was in 34 cases (8.2%), and parathyroid carcinoma was in 10 cases (2.4%). Compared with benign PHPT, serum PTH, calcium, alkaline phosphatase, and bone turnover marker (BTM) levels were significantly increased, and serum phosphate level was decreased in malignant PHPT. Conclusion: Clinical features of PHPT changed during 2013-2024 with remarkably increasing asymptomatic PHPT patients, whose clinical manifestations were milder, and complications were less.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.